Clinical trials: Experimental
Diabetes Mellitus, Type 2, Hypertension
Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
This study is to assess the safety and performance of the Neurotronic Infusion Catheter and ethanol denervation of renal and hepatic arteries for the treatment of patients with Type 2 Diabetes (T2DM), Hypertension and Obesity.
- Trial name
- NECTAR IV (NCT05369065)
- Testing
- Ablation Treatment, Arterial Angiography Only, Single Arm non-Randomized Ablation Treatment
- Where
- 3 sites in Georgia
- Volunteers
- 60 people
- Sponsor
- Neurotronic, Inc.
HIV Infections
Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects
The objective of this study is to determine the long term safety and tolerability of multiple oral doses of tipranavir (Aptivus) and ritonavir with a focus on the long term safety of the development dose (500 mg tipranavir/200 mg…
- Trial name
- NCT00146328
- Testing
- Tipranavir
- Where
- 233 sites in United States, Argentina and 16 more
- Volunteers
- 997 people
- Sponsor
- Boehringer Ingelheim
Exocrine Pancreatic Insufficiency
Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)
Protocol ALCT-0000497 is a multicenter safety, tolerability and fat absorption study that anticipates enrolling 35 male and female subjects (pediatric and adult) with cystic fibrosis.
- Trial name
- NCT02598128
- Testing
- RELiZORB
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Alcresta Therapeutics, Inc.
Chemotherapy-induced Neutropenia
Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Determination of the effect of balugrastim on the duration and severity of severe neutropenia.
- Trial name
- NEUGR-002 (NCT00837265)
- Testing
- Balugrastim, Pegfilgrastim, Chemotherapy Regimen
- Volunteers
- 334 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Depressive Disorder, Major, Suicidal
A Study of SLS-002 (Intranasal Racemic Ketamine) in Adults With Major Depressive Disorder at Imminent Risk of Suicide
The purpose of the study is to evaluate the efficacy, safety, and tolerability of SLS-002 (intranasal racemic ketamine) in addition to standard of care on symptoms of Major Depressive Disorder (MDD) and suicidality, in…
- Trial name
- NCT04669665
- Testing
- SLS-002, Standard of care, Intranasal device
- Where
- 21 sites in United States
- Volunteers
- 164 people
- Sponsor
- Seelos Therapeutics, Inc.
Atherosclerosis
Study to Determine the Effect of Repeated Administration of Diltiazem on the Pharmacokinetics of Darapladib (Sb-480848).
Darapladib (SB-480848) is a novel, selective, orally active inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2) currently under clinical development by GlaxoSmithKline as a potential anti-atherosclerosis agent for…
- Trial name
- NCT01852565
- Testing
- Darapladib, Diltiazem
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19, SARS-CoV2
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure…
- Trial name
- HERD (NCT04446065)
- Testing
- Previfenon®
- Volunteers
- healthy volunteers welcome
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA
Immune System Disorder, Healthy Volunteers
A Study to Assess the Effect of Oral Belumosudil on Inhibition of Various Proteins in the Fed State in Healthy Male Subjects
The purpose of this study is to evaluate safety and pharmacokinetics (PK) effect of belumosudil on the uridine diphosphate glucuronosyltransferase (UGT)1A1 (Part 1), P glycoprotein (P-gp) (Part 2) and breast cancer resistance…
- Trial name
- NCT05806567
- Testing
- Belumosudil, UGT1A1 victim drug, P-gp victim drug
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Kadmon, a Sanofi Company
Parkinson's Disease
A Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa
The purpose of this study is to establish the efficacy of 20 mg/day and 40 mg/day doses of istradefylline for reducing the mean total hours of awake time per day spent in the OFF state in patients with advanced Parkinson's…
- Trial name
- NCT00455507
- Testing
- Istradefylline
- Where
- Japan
- Volunteers
- 363 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chronic Obstructive Pulmonary Disease
Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this Phase III study is to evaluate the long-term safety and tolerability of two fixed-dose combinations of inhaled aclidinium bromide/formoterol fumarate, aclidinium bromide, formoterol fumarate and placebo in…
- Trial name
- NCT01572792
- Testing
- Aclidinium bromide/formoterol Fixed-Dose Combination (FDC), Aclidinium bromide, Formoterol Fumarate
- Where
- 208 sites in United States, Australia and 2 more
- Volunteers
- 921 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, NSCLC Adenocarcinoma
A Study of MGC028 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined).
- Conditions
- Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
- Trial name
- NCT06723236
- Testing
- MGC028
- Where
- 7 sites in United States
- Volunteers
- 124 people
- Sponsor
- MacroGenics
Psoriasis
Safety and Tolerability Study of MSC Exosome Ointment
This phase 1 study aims to evaluate the safety and tolerability of the application of the MSC exosome ointment with repeated topical application on adult healthy subjects (TID from Day 1 to 20).
- Trial name
- NCT05523011
- Testing
- Exosome ointment
- Where
- Singapore
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Paracrine Therapeutics Dermatology Pte. Ltd.
Dry Eye Disease, Dry Eye
Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye
Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for…
- Conditions
- Dry Eye Disease, Dry Eye, Dry Eyes Chronic, Dry Eye Syndromes
- Trial name
- CAMOMILE-2 (NCT06903611)
- Testing
- CAM-101, Vehicle Control
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Cambium Bio Limited
Infection, Intra-abdominal
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra…
- Trial name
- DRAGON (NCT00769171)
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone + Metronidazole
- Where
- 25 sites in China, Hong Kong and 4 more
- Volunteers
- 364 people
- Sponsor
- Bayer
Breast Cancer
A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients
This is the phase 2 portion of a phase 1/2 trial, testing the use of pemetrexed and cyclophosphamide in combination for the treatment of advanced breast cancer.
- Trial name
- NCT00190671
- Testing
- pemetrexed, cyclophosphamide
- Where
- 13 sites in Austria, Czechia and 4 more
- Volunteers
- 103 people
- Sponsor
- Eli Lilly and Company
Healthy
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
The purpose of this study is to assess the bioavailability, safety, and tolerability of a modified-release formulation of PF-05180999 relative to an immediate-release formulation in healthy adult subjects.
- Trial name
- NCT01530529
- Testing
- PF-05180999
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Hepatic Impairment
Pharmacokinetics and Safety of SHR0302 in Patients With Hepatic Impairment
Study to Evaluate Pharmacokinetics and Safety of SHR0302 in Patients With Mild, Moderate Hepatic Impairment and Normal Liver Function in Phase I Clinical Study
- Trial name
- NCT04293029
- Testing
- SHR0302
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
COPD
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD
Study for subjects 40 to 65 years-old with a diagnosis of moderate to severe COPD. Aclidinium bromide 400 mcg 2x a day will be given as an active comparator.
- Trial name
- GOLDEN 6 (NCT02038829)
- Testing
- SUN101 3 mcg, SUN-101 6.25 mcg, SUN-101 12.5 mcg
- Where
- 10 sites in United States
- Volunteers
- 96 people
- Sponsor
- Sunovion Respiratory Development Inc.
Labor Duration, Cesarean Section Rate
The MOBY Study: Efficacy of Birth Mobility
This randomized clinical trial investigates whether and how maternal mobility during labor influences birth outcomes in primiparous women.
- Conditions
- Labor Duration, Cesarean Section Rate, Maternal Mobility, Healthy
- Trial name
- MOBY (NCT07052331)
- Testing
- Birth Mobility System
- Where
- Switzerland
- Volunteers
- 714 people
- Sponsor
- Vibwife AG
Osteoarthritis
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With Osteoarthritis
We will evaluate the efficacy of PN 400 and an active comparator in patients that have Osteoarthritis of the knee.
- Trial name
- NCT00665431
- Testing
- PN 400 (VIMOVO), celebrex, Rescue Antacid
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- POZEN
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.